Drugs / S-nitrosoglutathione
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03926741 | Apr 2019 → Feb 2024 | asthma | James Reynolds | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-nitrosoglutathione | “GSNO is a chemical that protects people's airways. The initials stand for S-nitrosoglutathione, (pronounced s-nahy-troh-soh-gloo-tuh-thahy-ohn), and it is naturally produced by...” NCT03926741 ↗ |
| Known as | GSNO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03926741 ↗ |
| Modality | Small molecule | — CHEMBL63507 ↗ |
| Route | Inhaled | “use a nebulizer to inhale (breathe in) a solution of GSNO” NCT03926741 ↗ |